Brighton, UK, October 17, 2016 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has appointed Dr. John Ford as CEO with immediate effect. Enterprise Therapeutics is…
Edinburgh, Scotland, October 7, 2016 – At the OBN Awards 2016 dinner in Oxford last night, Edinburgh Molecular Imaging were awarded the Best Emerging Medtech Company Award. EM Imaging CEO Ian Wilson celebrates wining the Best Emerging Medtech Company Award at OBN 2016. The Awards, which…
LOUISVILLE, Ky., Aug. 8, 2016 – Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the expansion of its executive team with the addition of Dr. Robert Kim as its Chief Medical Officer. Dr. Kim will help the company optimize its drug development strategy as its clinical…
A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease Edinburgh, Scotland, July 28, 2016: Epidarex Capital today announces the launch of Nodthera Limited, a new biotech company focused on the discovery and development of novel inhibitors of the NLRP3…
Business Quarter interviews Sinclair Dunlop, Managing Partner of Epidarex Capital on venture capital, innovation, and the funding gap in Scotland. Click here for a link to the interview.
LOUISVILLE, Ky., June 23, 2016 – Apellis Pharmaceuticals, Inc. today announced positive results from two Phase 1 clinical trials of its complement C3 inhibitor, APL-2. The trials were randomized, double-blind, placebo-controlled, single and multiple ascending dose studies designed to assess the safety, tolerability, pharmacokinetics (PK)…
Glasgow, Scotland, UK, 20th June 2016: Mironid Ltd, a leader in cell signalling directed drug development, today announced the closing of its Series A funding round of £4.3 million ($6.2 million), which will support the Company’s internal research and preclinical development programmes, focused on degenerative…
Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes, is pleased to announce the following appointments: Dr Frank M Armstrong…
By Gareth Mackie, The Scotsman A university spin-out that specialises in potential treatments for type 2 diabetes has bolstered its boardroom in the wake of a £4.5 million cash injection. Glasgow-based Caldan Therapeutics, a spin-out from the universities of Glasgow and Southern Denmark, has appointed…
Edinburgh and Paris, April 6th, 2016 – Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical research collaboration to study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea’s confocal laser…